Media stories about Quotient (NASDAQ:QTNT) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Quotient earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1623007713084 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Separately, BidaskClub upgraded shares of Quotient from a “hold” rating to a “buy” rating in a report on Friday, March 16th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $12.50.
Shares of QTNT stock traded up $0.14 during midday trading on Wednesday, hitting $5.89. 407,120 shares of the stock were exchanged, compared to its average volume of 484,286. The stock has a market capitalization of $272.16, a P/E ratio of -2.57 and a beta of -0.03. Quotient has a 1-year low of $2.78 and a 1-year high of $7.74. The company has a current ratio of 2.34, a quick ratio of 1.65 and a debt-to-equity ratio of 22.54.
In related news, Director Prondzynski Heino Von bought 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were acquired at an average cost of $4.28 per share, with a total value of $51,360.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian Mcdonough bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average cost of $3.87 per share, for a total transaction of $38,700.00. Following the completion of the transaction, the director now directly owns 47,747 shares of the company’s stock, valued at approximately $184,780.89. The disclosure for this purchase can be found here. 29.00% of the stock is currently owned by company insiders.
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.